Dr. Lixue Xuan 宣立学
Chief Physician
Department of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of breast diseases, and nutritional support for cancer patients.
Dr. Xuan graduated from Bethune Medical University in 1987 and earned a doctoral degree in surgery in 1998, followed by a clinical medicine doctorate from the University of Bern, Switzerland. Dr. Xuan completed postdoctoral work in clinical surgery at Peking Union Medical College Hospital from December 1998 to February 2001. Research includes national and international projects on early-stage breast cancer. Dr. Xuan has received three ministerial-level awards, published over 40 papers, and co-authored four books.
Name order: in Chinese the family name comes first (Xuan Lixue). Papers usually list the name as Lixue Xuan or Xuan L.
Selected publications
19 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Gland Surg, 2026 (senior author): Development and validation of a survival-predicting nomogram for HER2-negative T1-3N0-1 breast cancer treated with breast-conserving surgery: a Surveillance, Epidemiology, and End Results (SEER) database analysis. PubMed 41808798
- Gland Surg, 2025 (senior author): Development and validation of nomograms predicting survival in female patients with HER2-positive T1-3N0-1 breast cancer following breast-conserving surgery: a Surveillance, Epidemiology, and End Results database analysis. PubMed 41377890
- Transl Cancer Res, 2025 (senior author): Development and validation of nomograms predicting survival in operable breast cancer patients at reproductive age after breast conserving surgery and postoperative radiotherapy based on SEER database. PubMed 41234837
- Front Mol Biosci, 2024 (senior author): Unraveling breast cancer prognosis: a novel model based on coagulation-related genes. PubMed 38751445
- J Cancer, 2024 (senior author): PD-1/PD-L1 Inhibitor - Related Adverse Events and Their Management in Breast Cancer. PubMed 38577606
- Front Oncol, 2023 (senior author): AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer. PubMed 37197416
- Front Pharmacol, 2022 (senior author): PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. PubMed 35370736
- J Cell Mol Med, 2022 (senior author): Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment. PubMed 35150062
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion